JNJ-75276617 (bleximenib) is active in the presence of wild-type and mutated menin. Mutations to MEN1 (menin), such as M327I and T349M, have been observed in patients with acquired clinical resistance to the menin-KMT2A inhibitor revumenib. Kwon et al show that the menin-KMT2A inhibitor JNJ-75276617 can block the interaction between KMT2A and wild-type menin or menin bearing the M327I or T349 mutation. JNJ-75276617 is also effective at inhibiting proliferation of cells expressing wild-type or mutant menin.